Novavax Inc NVAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVAX is a good fit for your portfolio.
News
-
Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
-
Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
-
Novavax Says It Can Deliver Recommended Covid Vaccine in September
-
Novavax to Participate in 2024 Jefferies Global Healthcare Conference
-
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia
-
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meeting
-
Novavax to Participate in BofA Securities 2024 Health Care Conference
-
Novavax Shares Pop Another 50% Following Sanofi Deal
Trading Information
- Previous Close Price
- $16.67
- Day Range
- $16.82–17.81
- 52-Week Range
- $3.53–23.86
- Bid/Ask
- $17.07 / $17.11
- Market Cap
- $2.52 Bil
- Volume/Avg
- 7.1 Mil / 16.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.46
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,992
- Website
- https://www.novavax.com
Comparables
Valuation
Metric
|
NVAX
|
MRNA
|
002007
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 23.55 |
Price/Book Value | — | 3.65 | 2.56 |
Price/Sales | 2.46 | 9.15 | 5.67 |
Price/Cash Flow | — | — | 28.96 |
Price/Earnings
NVAX
MRNA
002007
Financial Strength
Metric
|
NVAX
|
MRNA
|
002007
|
---|---|---|---|
Quick Ratio | 0.62 | 3.74 | 2.68 |
Current Ratio | 0.90 | 4.03 | 4.01 |
Interest Coverage | −26.84 | −148.54 | 140.38 |
Quick Ratio
NVAX
MRNA
002007
Profitability
Metric
|
NVAX
|
MRNA
|
002007
|
---|---|---|---|
Return on Assets (Normalized) | −20.87% | −28.15% | 10.96% |
Return on Equity (Normalized) | — | −37.30% | 15.42% |
Return on Invested Capital (Normalized) | — | −36.39% | 12.13% |
Return on Assets
NVAX
MRNA
002007
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Ghgppvyg | Fxnnw | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Rrbmqwhc | Zsnjpqw | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Mycvsvn | Zycflm | $118.7 Bil | |||
Moderna Inc
MRNA
| Qvyndqgt | Nbwx | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Llycbbdt | Ccgwlt | $29.7 Bil | |||
argenx SE ADR
ARGX
| Zsgvqlzgc | Vjms | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Cbrglwgm | Xhpv | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Kkkgfsgh | Rnjqv | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Kndclpsrk | Zyx | $15.0 Bil | |||
Incyte Corp
INCY
| Ykwfgqhq | Cqshyf | $13.5 Bil |